A phase 2 study comparing sequential satraplatin and erlotinib [Tarceva] to single-agent erlotinib in patients greater than or equal to 70 years of age with unresectable stage 3 or 4 non-small cell lung cancer as 1st-line therapy.

Trial Profile

A phase 2 study comparing sequential satraplatin and erlotinib [Tarceva] to single-agent erlotinib in patients greater than or equal to 70 years of age with unresectable stage 3 or 4 non-small cell lung cancer as 1st-line therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2012

At a glance

  • Drugs Erlotinib; Satraplatin
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Apr 2012 Actual patient number is 100 according to ClinicalTrials.gov.
    • 30 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Sep 2008 Checked against clinicaltrials.gov record, updated status, end date and locations.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top